The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases
Open accessAbstract
Oligonucleotide-based therapies are advanced novel interventions used in the management of various respiratory diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD). These agents primarily act by gene silencing or RNA interference. Better methodologies and techniques are the need of the hour that can deliver these agents to tissues and cells in a target specific manner by which their maximum potential can be reached in the management of chronic inflammatory diseases. Nanoparticles play an important role in the target-specific delivery of drugs. In addition, oligonucleotides also are extensively used for gene transfer in the form of polymeric, liposomal and inorganic carrier materials. Therefore, the current review focuses on various novel dosage forms like nanoparticles, liposomes that can be used efficiently for the delivery of various oligonucleotides such as siRNA and miRNA. We also discuss the future perspectives and targets for oligonucleotides in the management of respiratory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949 · cited 1×
“cause prolonged silencing of endogenous miRNA [101].”
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Directed Self-Assembly of Nanoparticles
Grzelczak, M., Vermant, J., Furst, E. M., & Liz-Marzán, L. M. (2010) · ACS Nano · doi:10.1021/nn100869j · Cited by 2,215
Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792
Drug delivery systems: An updated review
Tiwari, G., Tiwari, R., Bannerjee, S., Bhati, L., Pandey, S., Pandey, P., & Sriwastawa, B. (2012) · International Journal of Pharmaceutical Investigation · doi:10.4103/2230-973x.96920 · Cited by 1,671
Self-citationChitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency
Mao, H.-Q., Roy, K., Troung-Le, V. L., Janes, K. A., Lin, K. Y., Wang, Y., August, J. T., & Leong, K. W. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00361-8 · Cited by 1,228
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081 · cited 2×
“In addition, they also have the potential of being used in various complex disorders such as different types of cancers and neurodegenerative disorders [9].”
BackgroundAntisense technologies: Improvement through novel chemical modifications
Kurreck, J. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03555.x · Cited by 1,006
MicroRNAs: Synthesis, mechanism, function, and recent clinical trials
Wahid, F., Shehzad, A., Khan, T., & Kim, Y. Y. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.06.013 · Cited by 899
The delivery of therapeutic oligonucleotides
Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 854
Aptamers and Their Biological Applications
Song, K.-M., Lee, S., & Ban, C. (2012) · Sensors · doi:10.3390/s120100612 · Cited by 821
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788
Polymeric nanoparticles: A study on the preparation variables and characterization methods
Crucho, C. I. C., & Barros, M. T. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.06.004 · Cited by 696
Design and gene delivery activity of modified polyethylenimines
Kircheis, R., Wightman, L., & Wagner, E. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00202-2 · Cited by 651
Niosome: A future of targeted drug delivery systems
Kuotsu, K., Karim, K., Mandal, A., Biswas, N., Guha, A., Chatterjee, S., & Behera, M. (2010) · Journal of Advanced Pharmaceutical Technology & Research · doi:10.4103/0110-5558.76435 · Cited by 626
FDA-Approved Oligonucleotide Therapies in 2017
Stein, C. A., & Castanotto, D. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.023 · Cited by 608
RNA Interference in Vitro and in Vivo Using a Novel Chitosan/siRNA Nanoparticle System
Howard, K. A., Rahbek, U. L., Liu, X., Damgaard, C. K., Glud, S. Z., Andersen, M. Ø., Hovgaard, M. B., Schmitz, A., Nyengaard, J. R., Besenbacher, F., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.04.010 · Cited by 585
Advances of Non-Ionic Surfactant Vesicles (Niosomes) and Their Application in Drug Delivery
Ge, X., Wei, M., He, S., & Yuan, W.-E. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11020055 · Cited by 578
Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma.
Kline, J. N., Waldschmidt, T. J., Businga, T. R., Lemish, J. E., Weinstock, J. V., Thorne, P. S., & KRIEG, A. M. (1998) · PubMed · Cited by 546
DNA-polycation nanospheres as non-viral gene delivery vehicles
Leong, K. W., Mao, H.-Q., Truong-Le, V. L., Roy, K., Walsh, S. M., & August, J. T. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)00252-6 · Cited by 538
Köping-Höggård, M., Tubulekas, I., Guan, H., Edwards, K., Nilsson, M., Vårum, K., & Artursson, P. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301492 · Cited by 532
Characterization of commercially available and synthesized polyethylenimines for gene delivery
von Harpe, A., Petersen, H., Li, Y., & Kissel, T. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00317-5 · Cited by 519
Microencapsulated chitosan nanoparticles for lung protein delivery
Grenha, A., Seijo, B., & Remuñán-López, C. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.04.009 · Cited by 469
Nanoparticle-Mediated Pulmonary Drug Delivery: A Review
Paranjpe, M., & Müller-Goymann, C. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15045852 · Cited by 454
Kline, J. N., Waldschmidt, T. J., Businga, T. R., Lemish, J. E., Weinstock, J. V., Thorne, P. S., & Krieg, A. M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.6.2555 · Cited by 446
Taratula, O., Kuzmov, A., Shah, M., Garbuzenko, O. B., & Minko, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.018 · Cited by 416
Röthlisberger, P., & Hollenstein, M. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.007 · Cited by 413
Borchard, G., Lueβen, H. L., de Boer, A. G., Verhoef, J. C., Lehr, C.-M., & Junginger, H. E. (1996) · Journal of Controlled Release · doi:10.1016/0168-3659(95)00146-8 · Cited by 393
The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing
Liu, X., Howard, K. A., Dong, M., Andersen, M. Ø., Rahbek, U. L., Johnsen, M. G., Hansen, O. C., Besenbacher, F., & Kjems, J. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.11.004 · Cited by 391
Zhang, W., Yang, H., Kong, X., Mohapatra, S., Juan-Vergara, H. S., Hellermann, G., Behera, S., Singam, R., Lockey, R. F., & Mohapatra, S. S. (2005) · Nature Medicine · doi:10.1038/nm1174 · Cited by 365
Perez, C., Sanchez, A., Putnam, D., Ting, D., Langer, R., & Alonso, M. J. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00397-2 · Cited by 313
Biodegradable polymeric nanocarriers for pulmonary drug delivery
Rytting, E., Nguyen, J., Wang, X., & Kissel, T. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.6.629 · Cited by 266
PLGA–PEI nanoparticles for gene delivery to pulmonary epithelium
Bivas-Benita, M., Romeijn, S., Junginger, H. E., & Borchard, G. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.03.008 · Cited by 256
Biodistribution of phosphodiester and phosphorothioate siRNA
Braasch, D. A., Paroo, Z., Constantinescu, A., Ren, G., Öz, O. K., Mason, R. P., & Corey, D. R. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.12.074 · Cited by 251
Taratula, O., Garbuzenko, O. B., Chen, A. M., & Minko, T. (2011) · Journal of Drug Targeting · doi:10.3109/1061186x.2011.622404 · Cited by 245
Vandamme (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s1045 · Cited by 238
Nanomedicine based approaches for the delivery of siRNA in cancer
Ozpolat, B., Sood, A. K., & Lopez‐Berestein, G. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02191.x · Cited by 218
PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy
Osman, G., Rodriguez, J., Chan, S. Y., Chisholm, J., Duncan, G., Kim, N., Tatler, A. L., Shakesheff, K. M., Hanes, J., Suk, J. S., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.001 · Cited by 208
Bivas-Benita, M., van Meijgaarden, K. E., Franken, K. L. M. C., Junginger, H. E., Borchard, G., Ottenhoff, T. H. M., & Geluk, A. (2004) · Vaccine · doi:10.1016/j.vaccine.2003.09.044 · Cited by 195
Gursel, I., Gursel, M., Ishii, K. J., & Klinman, D. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.6.3324 · Cited by 182
Garbuzenko, O. B., Saad, M., Betigeri, S., Zhang, M., Vetcher, A. A., Soldatenkov, V. A., Reimer, D. C., Pozharov, V. P., & Minko, T. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9755-4 · Cited by 167
Conde, J., Tian, F., Hernández, Y., Bao, C., Cui, D., Janssen, K., Ibarra, M. R., Baptista, P. V., Stoeger, T., & de la Fuente, J. M. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.06.041 · Cited by 154
Li, F., Mei, H., Gao, Y., Xie, X., Nie, H., Li, T., Zhang, H., & Jia, L. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.08.030 · Cited by 152 · cited 1×
“These liposomes are shown to have improved stability and additionally provided controlled discharge of drugs [32].”
BackgroundCellular uptake and intracellular trafficking of oligonucleotides
Juliano, R. L., & Carver, K. A. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.04.005 · Cited by 149
Dendrimer-Inspired Nanomaterials for the in Vivo Delivery of siRNA to Lung Vasculature
Khan, O. F., Zaia, E. W., Jhunjhunwala, S., Xue, W., Cai, W., Yun, D. S., Barnés, C. M., Dahlman, J. E., Dong, Y., Pelet, J. M., et al. (2015) · Nano Letters · doi:10.1021/nl5048972 · Cited by 146
CpG Oligonucleotides as Cancer Vaccine Adjuvants
Shirota, H., Tross, D., & Klinman, D. M. (2015) · Vaccines · doi:10.3390/vaccines3020390 · Cited by 143
An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies
McClorey, G., & Wood, M. J. A. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.07.005 · Cited by 142
Oligonucleotide therapeutic approaches for Huntington disease
Sah, D. W. Y., & Aronin, N. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45130 · Cited by 137
Iqbal, M., Lin, W., Jabbal‐Gill, I., Davis, S. S., Steward, M. W., & Illum, L. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00662-x · Cited by 136
Dykxhoorn, D. M., & Lieberman, J. (2006) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.8.061505.095848 · Cited by 134
Chitosan IFN-γ-pDNA Nanoparticle (CIN) Therapy for Allergic Asthma
Kumar, M., Kong, X., Behera, A. K., Hellermann, G. R., Lockey, R. F., & Mohapatra, S. S. (2003) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-1-3 · Cited by 131
Nascimento, A. V., Singh, A., Bousbaa, H., Ferreira, D., Sarmento, B. F. C. C., & Amiji, M. M. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.09.045 · Cited by 131
Xie, Y., Kim, N. H., Nadithe, V., Schalk, D. L., Thakur, A. B., Kılıç, A., Lum, L. G., Bassett, D. J. P., & Merkel, O. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.03.029 · Cited by 130
Dua, K., Malyla, V., Singhvi, G., Wadhwa, R., Krishna, R. V., Shukla, S. D., Shastri, M. D., Chellappan, D. K., Maurya, P. K., Satija, S., et al. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.12.009 · Cited by 130
Self-citationRaghuwanshi, D., Mishra, V., Das, D., Kaur, K., & Suresh, M. R. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200553x · Cited by 126
Bae, K. H., Lee, J. Y., Hyeon, L. S., Park, T. G., & Nam, Y. S. (2012) · Advanced Healthcare Materials · doi:10.1002/adhm.201200338 · Cited by 116
Conti, D. S., Brewer, D., Grashik, J., Avasarala, S., & da Rocha, S. R. P. (2014) · Molecular Pharmaceutics · doi:10.1021/mp4006358 · Cited by 116
Mehta, M., Deeksha, Sharma, N., Vyas, M., Khurana, N., Maurya, P. K., Singh, H., de Jesus, T. P. A., Dureja, H., Chellappan, D. K., et al. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.02.021 · Cited by 112
Self-citationTherapeutic antisense oligonucleotides against cancer: hurdling to the clinic
Moreno, P. M. D., & Pêgo, A. P. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00087 · Cited by 111
Nonviral Pulmonary Delivery of siRNA
Merkel, O. M., & Kissel, T. (2011) · Accounts of Chemical Research · doi:10.1021/ar200110p · Cited by 104
Xu, C., Jere, D., Jin, H., Chang, S.-H., Chung, Y.-S., Shin, J., Kim, J., Park, S. J., Lee, Y.-H., Chae, C., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200707-1022oc · Cited by 102
Application of Dendrimers for the Treatment of Infectious Diseases
Mhlwatika, Z., & Aderibigbe, B. A. (2018) · Molecules · doi:10.3390/molecules23092205 · Cited by 97 · cited 1×
“Due to such unique properties, dendrimers are becoming an useful drug delivery system [87].”
BackgroundNanotechnology in respiratory medicine
Omlor, A., Nguyen, J., Bals, R., & Dinh, Q. T. (2015) · Respiratory Research · doi:10.1186/s12931-015-0223-5 · Cited by 95
Lipid-based vectors for siRNA delivery
Zhang, S., Zhi, D., & Huang, L. (2012) · Journal of drug targeting · doi:10.3109/1061186x.2012.719232 · Cited by 95
Dua, K., Rapalli, V. K., Shukla, S. D., Singhvi, G., Shastri, M. D., Chellappan, D. K., Satija, S., Mehta, M., Gulati, M., Pinto, T. D. J. A., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.101 · Cited by 95
Self-citationKang, S. P., & Saif, M. W. (2007) · PubMed · Cited by 93
Attenuation of fibrosis in vitro and in vivo with SPARC siRNA
Wang, J.-C., Lai, S., Guo, X., Zhang, X., Crombrugghe, B. D., Sonnylal, S., Arnett, F. C., & Zhou, X. (2010) · Arthritis Research & Therapy · doi:10.1186/ar2973 · Cited by 90
Roth, S. B., Jalava, J., Ruuskanen, O., Ruohola, A., & Nikkari, S. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.9.4268-4274.2004 · Cited by 80
Oligonucleotide therapeutics in neurodegenerative diseases
Scoles, D. R., & Pulst, S. M. (2018) · RNA Biology · doi:10.1080/15476286.2018.1454812 · Cited by 80
Delivery of RNAi Therapeutics to the Airways—From Bench to Bedside
Qiu, Y., Lam, J. K. W., Leung, S. W. S., & Liang, W. (2016) · Molecules · doi:10.3390/molecules21091249 · Cited by 77
McCaskill, J. L., Singhania, R., Burgess, M. L., Allavena, R., Wu, S. Y., Blumenthal, A., & McMillan, N. A. J. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.22 · Cited by 73
Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration
von Beust, B. R., Johansen, P., Smith, K. A., Bot, A. I., Storni, T., & Kündig, T. M. (2005) · European Journal of Immunology · doi:10.1002/eji.200526124 · Cited by 71
Intranasal IFN-γ gene transfer protects BALB/c mice against respiratory syncytial virus infection
Kumar, M., Behera, A. K., Matsuse, H., Lockey, R. F., & Mohapatra, S. S. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00185-1 · Cited by 67
Sustained delivery by leucine-modified chitosan spray-dried respirable powders
Learoyd, T. P., Burrows, J. L., French, E., & Seville, P. C. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.01.017 · Cited by 64
Otsuka, M., Shiratori, M., Chiba, H., Kuronuma, K., Sato, Y., Niitsu, Y., & Takahashi, H. (2017) · Experimental Lung Research · doi:10.1080/01902148.2017.1354946 · Cited by 63
Hattori, Y., Nakamura, M., Takeuchi, N., et al. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1502775 · Cited by 62
Kong, X., Zhang, W., Lockey, R. F., Auais, A., Piedimonte, G., & Mohapatra, S. S. (2007) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-5-4 · Cited by 60
Hatano, K., Matsubara, T., Muramatsu, Y., Ezure, M., Koyama, T., Matsuoka, K., Kuriyama, R., Kori, H., & Sato, T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5007676 · Cited by 60
Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease
Seguin, R. M., & Ferrari, N. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903179294 · Cited by 59
Joshi, V. B., Adamcakova‐Dodd, A., Jing, X., Wongrakpanich, A., Gibson-Corley, K. N., Thorne, P. S., & Salem, A. K. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9624-5 · Cited by 59
Yoon, P. O., Park, J. W., Lee, C., Kim, S. H., Kim, H., Ko, Y., Bae, S. J., Yun, S., Park, J. H., Kwon, T., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.693671 · Cited by 57
Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis
Sermet‐Gaudelus, I., Clancy, J. P., Nichols, D. P., Nick, J. A., Boeck, K. D., Solomon, G. M., Mall, M. A., Bolognese, J. A., Bouisset, F., den Hollander, W., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.10.015 · Cited by 57
Pellosi, D. S., d’Angelo, I., Maiolino, S., Mitidieri, E., Bianca, R. D. D. V., Sorrentino, R., Quaglia, F., & Ungaro, F. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.06.006 · Cited by 56
Polycation-based nanoparticle delivery for improved RNA interference therapeutics
Howard, K. A., & Kjems, J. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.12.1811 · Cited by 55
Glud, S. Z., Bramsen, J. B., Dagnæs‐Hansen, F., Wengel, J., Howard, K. A., Nyengaard, J. R., & Kjems, J. (2009) · Oligonucleotides · doi:10.1089/oli.2008.0175 · Cited by 54
Characterization of Polymeric Micelles for Pulmonary Delivery of Beclomethasone Dipropionate
Gaber, N. N., Darwis, Y., Peh, K.-K., & Tan, Y. T.-F. (2006) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2006.426 · Cited by 53
siRNA and the lung: research tool or therapeutic drug?
de Fougerolles, A., & Novobrantseva, T. I. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.04.005 · Cited by 49
Oligonucleotide Therapy for Obstructive and Restrictive Respiratory Diseases
Liao, W., Dong, J., Peh, H. Y., Tan, L., Lim, K., Li, L., & Wong, W. S. F. (2017) · Molecules · doi:10.3390/molecules22010139 · Cited by 48
Dendrimer Nanocarriers for Transport Modulation Across Models of the Pulmonary Epithelium
Bharatwaj, B., Mohammad, A. K., Dimovski, R., Cássio, F. L., Bazito, R. C., Conti, D. S., Fu, Q., Reineke, J., & da Rocha, S. R. P. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500662z · Cited by 46
Sung, D. K., Kong, W. H., Park, K., Kim, J. H., Kim, M. Y., Kim, H., & Hahn, S. K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.061 · Cited by 43
An Imperative Note on Novel Drug Delivery Systems
Bheemidi, V. S. (2011) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000125 · Cited by 43
MicroRNAs as therapeutics for future drug delivery systems in treatment of lung diseases
Dua, K., Hansbro, N. G., Foster, P. S., & Hansbro, P. M. (2016) · Drug Delivery and Translational Research · doi:10.1007/s13346-016-0343-6 · Cited by 43
Self-citationWang, X., Xu, W., Mohapatra, S., Kong, X., Li, X., Lockey, R. F., & Mohapatra, S. S. (2008) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-6-7 · Cited by 41
Trainer, P. J., Newell-Price, J. D. C., Ayuk, J., Aylwin, S. J. B., Rees, A., Drake, W. M., Chanson, P., Brue, T. C., Webb, S. M., Fajardo, C., et al. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0138 · Cited by 40
Nafee, N. A., Schneider, M., Friebel, K., Dong, M., Schaefer, U. F., Mürdter, T. E., & Lehr, C. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.11.019 · Cited by 39
Antisense Oligonucleotide Therapy in Diabetic Retinopathy
Hnik, P., Boyer, D. S., Grillone, L. R., Clement, J. G., Henry, S. P., & Green, E. A. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300440 · Cited by 36
Multitargeted Approach Using Antisense Oligonucleotides for the Treatment of Asthma
Allakhverdi, Z., ALLAM, M., GUIMOND, A., FERRARI, N., ZEMZOUMI, K., Seguin, R. M., Paquet, L., & RENZI, P. M. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1348.047 · Cited by 31
Nanotechnology: Advancing the translational respiratory research
Dua, K., Shukla, S. D., Pinto, T. D. J. A., & Hansbro, P. M. (2017) · Interventional Medicine and Applied Science · doi:10.1556/1646.9.2017.1.02 · Cited by 31
Self-citationA review of antisense therapeutic interventions for molecular biological targets in asthma.
Popescu, F., & Popescu, F. (2007) · PubMed Central · Cited by 27
Oligonucleotides: A Multi-Targeted Approach for the Treatment of Respiratory Diseases
Ferrari, N., Seguin, R. M., & RENZI, P. M. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.108 · Cited by 18
Cited by
Mehta, M., Dhanjal, D. S., Paudel, K. R., Singh, B., Gupta, G., Rajeshkumar, S., Thangavelu, L., Tambuwala, M. M., Bakshi, H. A., Chellappan, D. K., et al. (2020) · Inflammopharmacology · doi:10.1007/s10787-020-00698-3 · Cited by 330
Self-citation
Metadata
- Authors
- Mehta, M., Deeksha, Tewari, D., Gupta, G., Awasthi, R., Singh, H., Pandey, P., Chellappan, D. K., Wadhwa, R., Collet, T., Hansbro, P. M., Kumar, S. R., Thangavelu, L., Negi, P., Dua, K., & Satija, S.
- Venue
- Chemico-Biological Interactions
- Publisher
- Elsevier BV
- Published
- 2019-08
- Volume
- 308
- Pages
- 206-215
- ISSN
- 0009-2797 (ISSN-L)
- OpenAlex
- W2945719950
- Cited by
- 397
- References
- 101
- FWCI
- 17.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.